Resverlogix Corp.
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. The company's lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary sy… Read more
Resverlogix Corp. (RVXCF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.009x
Based on the latest financial reports, Resverlogix Corp. (RVXCF) has a cash flow conversion efficiency ratio of 0.009x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-818.00K) by net assets ($-88.89 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Resverlogix Corp. - Cash Flow Conversion Efficiency Trend (2001–2024)
This chart illustrates how Resverlogix Corp.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Resverlogix Corp. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Resverlogix Corp. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chiangmai Frozen Foods Public Company Limited
BK:CM
|
-0.032x |
|
Aquaron Acquisition Corp. Common Stock
NASDAQ:AQU
|
-0.032x |
|
Kurniamitra Duta Sentosa Tbk
JK:KMDS
|
0.002x |
|
Odonate Inc.
PINK:ODTCD
|
N/A |
|
SANCY BERHAD
KLSE:03057
|
N/A |
|
POSaBIT Systems Corp
OTCQB:POSAF
|
-0.469x |
|
Viet Thang Corp
VN:TVT
|
N/A |
|
Hasen-Immobilien AG
STU:ABHA
|
0.010x |
Annual Cash Flow Conversion Efficiency for Resverlogix Corp. (2001–2024)
The table below shows the annual cash flow conversion efficiency of Resverlogix Corp. from 2001 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-81.73 Million | $-3.89 Million | 0.048x | +40.95% |
| 2023-12-31 | $-74.47 Million | $-2.51 Million | 0.034x | -43.53% |
| 2022-12-31 | $-59.28 Million | $-3.54 Million | 0.060x | -55.43% |
| 2021-12-31 | $-59.87 Million | $-8.02 Million | 0.134x | -50.46% |
| 2019-12-31 | $-64.11 Million | $-17.34 Million | 0.271x | +15.07% |
| 2018-12-31 | $-207.72 Million | $-48.83 Million | 0.235x | -21.73% |
| 2017-12-31 | $-83.68 Million | $-25.13 Million | 0.300x | +34.58% |
| 2016-12-31 | $-101.57 Million | $-22.67 Million | 0.223x | -41.21% |
| 2015-12-31 | $-56.43 Million | $-21.42 Million | 0.380x | +229.32% |
| 2014-12-31 | $-73.73 Million | $-8.50 Million | 0.115x | -44.74% |
| 2013-12-31 | $-63.22 Million | $-13.19 Million | 0.209x | -78.77% |
| 2012-12-31 | $-29.50 Million | $-29.00 Million | 0.983x | +111.21% |
| 2011-12-31 | $2.74 Million | $-24.03 Million | -8.766x | -293.81% |
| 2010-12-31 | $-4.00 Million | $-18.11 Million | 4.523x | +210.10% |
| 2009-12-31 | $4.46 Million | $-18.34 Million | -4.108x | -240.55% |
| 2008-12-31 | $11.61 Million | $-14.00 Million | -1.206x | +66.59% |
| 2007-12-31 | $5.44 Million | $-19.65 Million | -3.611x | -137.13% |
| 2006-12-31 | $-1.02 Million | $-9.93 Million | 9.724x | +1749.37% |
| 2005-12-31 | $7.48 Million | $-4.41 Million | -0.590x | -166.26% |
| 2004-12-31 | $9.84 Million | $-2.18 Million | -0.221x | +35.03% |
| 2003-12-31 | $2.60 Million | $-885.04K | -0.341x | +29.20% |
| 2002-12-31 | $942.21K | $-453.56K | -0.481x | +0.20% |
| 2001-12-31 | $331.37K | $-159.84K | -0.482x | -- |